Madrigal Pharmaceuticals, Inc. Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

MDGL

Classement en actions #2020
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Prix de l'action
$445.70
Capitalisation boursière
$10.30B
Changement (1 jour)
-0.90%
Changement (1 an)
1.55%
Pays
US
Échange Madrigal Pharmaceuticals, Inc. (MDGL)

Catégorie

Healthcare
Historique des dividendes pour Madrigal Pharmaceuticals, Inc. (MDGL)
Madrigal Pharmaceuticals, Inc. (symbole boursier : MDGL) a versé un total de 0 dividendes.
Le total des dividendes (ajusté en fonction des divisions d’actions) est de : 0.00
Rendement du dividende (TTM) : 0
Versements de dividendes pour Madrigal Pharmaceuticals, Inc. (MDGL) de 2026 à 2026
Versements annuels de dividendes
Année Dividende (ajusté pour divisions d’actions) Changez
Pas assez de données pour les dates fournies.
Liste de tous les paiements de dividendes
Année Dividende Changez
Pas assez de données pour les dates fournies.
Dividendes versés par des entreprises similaires ou concurrentes
Entreprise Nombre de paiements de dividendes Pays
0.00%
US
0.00%
US
64.00%
AU
0.00%
CH
0.00%
NL